Schmidt Amy E, Sun Mao-fu, Ogawa Taketoshi, Bajaj S Paul, Gailani David
UCLA/Orthopaedic Hospital, Department of Orthopaedic Surgery and Molecular Biology Institute, David Geffen School of Medicine at UCLA, Los Angeles, California 90095, USA.
Biochemistry. 2008 Feb 5;47(5):1326-35. doi: 10.1021/bi701594j. Epub 2008 Jan 11.
In serine proteases, Gly193 (chymotrypsin numbering) is conserved with rare exception. Mutants of blood coagulation proteases have been reported with Glu, Ala, Arg or Val substitutions for Gly193. To further understand the role of Gly193 in protease activity, we replaced it with Ala or Val in coagulation factor XIa (FXIa). For comparison to the reported FXIa Glu193 mutant, we prepared FXIa with Asp (short side chain) or Lys (opposite charge) substitutions. Binding of p-aminobenzamidine (pAB) and diisopropylfluorphosphate (DFP) were impaired 1.6-36-fold and 35-478-fold, respectively, indicating distortion of, or altered accessibility to, the S1 and oxyanion-binding sites. Val or Asp substitutions caused the most impairment. Salt bridge formation between the amino terminus of the mature protease moiety at Ile16 and Asp194, essential for catalysis, was impaired 1.4-4-fold. Mutations reduced catalytic efficiency of tripeptide substrate hydrolysis 6-280-fold, with Val or Asp causing the most impairment. Further studies were directed toward macromolecular interactions with the FXIa mutants. kcat for factor IX activation was reduced 8-fold for Ala and 400-1100-fold for other mutants, while binding of the inhibitors antithrombin and amyloid beta-precursor protein Kunitz domain (APPI) was impaired 13-2300-fold and 22-27000-fold, respectively. The data indicate that beta-branching of the side chain of residue 193 is deleterious for interactions with pAB, DFP and amidolytic substrates, situations where no S2'-P2' interactions are involved. When an S2'-P2' interaction is involved (factor IX, antithrombin, APPI), beta-branching and increased side chain length are detrimental. Molecular models indicate that the mutants have impaired S2' binding sites and that beta-branching causes steric conflicts with the FXIa 140-loop, which could perturb the local tertiary structure of the protease domain. In conclusion, enzyme activity is impaired in FXIa when Gly193 is replaced by a non-Gly residue, and residues with side chains that branch at the beta-carbon have the greatest effect on catalysis and binding of substrates.
在丝氨酸蛋白酶中,Gly193(胰凝乳蛋白酶编号)几乎总是保守的。已有报道称凝血蛋白酶的突变体中,Gly193被Glu、Ala、Arg或Val取代。为了进一步了解Gly193在蛋白酶活性中的作用,我们在凝血因子XIa(FXIa)中将其替换为Ala或Val。为了与已报道的FXIa Glu193突变体进行比较,我们制备了用Asp(短侧链)或Lys(相反电荷)取代的FXIa。对氨基苯甲脒(pAB)和二异丙基氟磷酸酯(DFP)的结合分别受损1.6至36倍和35至478倍,表明S1和氧阴离子结合位点发生了扭曲或可及性改变。Val或Asp取代造成的损害最大。成熟蛋白酶部分Ile16处的氨基末端与Asp194之间形成的对催化至关重要的盐桥受损1.4至4倍。突变使三肽底物水解的催化效率降低了6至280倍,其中Val或Asp造成的损害最大。进一步的研究针对与FXIa突变体的大分子相互作用。因子IX激活的kcat对于Ala降低了8倍,对于其他突变体降低了400至1100倍,而抑制剂抗凝血酶和淀粉样β前体蛋白Kunitz结构域(APPI)的结合分别受损13至2300倍和22至27000倍。数据表明,在不涉及S2'-P2'相互作用的情况下,残基193侧链的β分支不利于与pAB、DFP和酰胺分解底物的相互作用。当涉及S2'-P2'相互作用时(因子IX、抗凝血酶、APPI),β分支和增加的侧链长度是有害的。分子模型表明,突变体的S2'结合位点受损,并且β分支与FXIa 140环发生空间冲突,这可能扰乱蛋白酶结构域的局部三级结构。总之,当Gly193被非Gly残基取代时,FXIa中的酶活性受损,并且在β-碳处分支的侧链残基对催化和底物结合的影响最大。